Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Atopic Dermatitis: Update Bulletin [December 2017]

Product Code:
596200939
Publication Date:
December 2017
Format:
PDF
Price:
£910

This edition presents the views and insights from three key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the atopic dermatitis (AD) market, including; Vanda Pharmaceuticals’ announcement of results from an 8-week randomised Phase II clinical study of tradipitant as a monotherapy in the treatment of chronic pruritus in patients with atopic dermatitis; Sanofi and Regeneron’s announcement of positive results from the Phase III CAFÉ study of Dupixent (dupilumab) in adults with moderate-to-severe atopic dermatitis who are inadequately controlled with, or intolerant to the broad immunosuppressant drug cyclosporine A (CSA), or when this treatment is medically inadvisable; and AnaptysBio’s announcement of positive proof-of-concept data for ANB020, its investigational anti-IL-33 monoclonal antibody (mAb), in an ongoing Phase IIa clinical trial in adult patients with moderate-to-severe atopic dermatitis.

Business Questions:

• Are KOLs optimistic about tradipitant’s mechanism of action and its potential in the management of chronic pruritus in patients with AD?
• What do KOLs recommend for Phase III studies with  tradipitant, and should Vanda Pharmaceuticals include biomarker and gene expression data?
• What impact will tradipitant’s oral formulation have on the product’s attractiveness?
• Are KOLs concerned about the price of tradipitant, and do they believe it can work as a monotherapy?
• Where do KOLs predict that tradipitant will be used in the treatment paradigm; as an adjunctive therapy, as a monotherapy, or in combination with other treatments?
• Do KOLs view the CAFÉ study as a significant step forward, and what impact will it have on the need to use cyclosporine A?
• How do KOLs see the future treatment paradigm of atopic dermatitis evolving as it relates to combination biologic approaches?
• Are KOLs excited about ANB020’s mechanism of action, or does the targeting of IL-33 as a potential treatment strategy for atopic dermatitis have a valid biological rationale?
• What were  KOL reactions to the Phase II data for ANB020, and what will KOLs look for from Phase III studies?
• 
What will be the key drivers of use for ANB020; clinical data, cost or both?




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved